The Retatrutide Dosing Schedule From Phase 2 Clinical Trials The Phase 2 trial (published in the New England Journal of Medicine) tested four retatrutide dosing schedule arms at target doses of 1mg, 4mg, 8mg, and 12mg weekly
As our understanding deepens, we can expect even more powerful, targeted, and safer medications that harness the full potential of GLP-1 biology
Instead, the art of diabetes care lies in tailoring therapy to the patient, ensuring both clinical effectiveness and quality of life
What is most disturbing is the rise in children under the age of 5 who are now overweight or living with obesity
Retatrutides stimulation of GCG receptors is believed to enhance metabolic rate and boost energy expenditure, further facilitating weight loss [15]